Recent Investment Analysts’ Ratings Changes for Liquidia (LQDA)

Several analysts have recently updated their ratings and price targets for Liquidia (NASDAQ: LQDA):

• 11/4/2025 – Liquidia had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a “buy” rating on the stock.
• 11/4/2025 – Liquidia had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $47.00 price target on the stock.
• 11/4/2025 – Liquidia had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock.
• 11/4/2025 – Liquidia had its price target raised by analysts at Needham & Company LLC from $36.00 to $52.00. They now have a “buy” rating on the stock.
• 11/3/2025 – Liquidia had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $45.00 price target on the stock.
• 10/20/2025 – Liquidia is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $31.00 price target on the stock.
• 10/8/2025 – Liquidia had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Liquidia had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
• 9/27/2025 – Liquidia had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, CAO Dana Boyle sold 1,238 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $23.41, for a total transaction of $28,981.58. Following the completion of the sale, the chief accounting officer directly owned 185,411 shares of the company’s stock, valued at approximately $4,340,471.51. This represents a 0.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 5,327 shares of the company’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $23.41, for a total transaction of $124,705.07. Following the sale, the insider directly owned 247,930 shares of the company’s stock, valued at approximately $5,804,041.30. This trade represents a 2.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 849,141 shares of company stock worth $23,584,920 in the last quarter. Insiders own 26.50% of the company’s stock.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).